Press Releases | Medtronic

Month Year

Email alerts

Aug 1, 2017

FIRE AND ICE Trial Analysis Shows Medtronic Cryoballoon Reduces Healthcare System Costs and Utilization

Data from Landmark Trial Published in the Journal of the American Heart Association

DUBLIN - August 1, 2017 - A new health economic analysis from the landmark FIRE AND ICE Trial, sponsored by Medtronic plc (NYSE: MDT), was published today in the Journal of the American Heart...
Jul 31, 2017

Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

DUBLIN - July 31, 2017 - Medtronic plc (NYSE:MDT) today announced CE (Conformité Européenne) mark and European launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic...
Jul 30, 2017

Medtronic Completes Sale of a Portion of Its Patient Monitoring & Recovery Division to Cardinal Health

DUBLIN - July 30, 2017 - Medtronic plc (NYSE: MDT) today announced that it has completed the previously announced sale of its Patient Care, Deep Vein Thrombosis (Compression), and Nutritional...
Jul 17, 2017

Five-Year Data Demonstrate InterStim(TM) Therapy Offers Sustained Long-Term Efficacy and Quality of Life Improvements for Overactive Bladder Patients

The InterStim System is the Only Proven, Long-Term Sacral Neuromodulation Solution for Overactive Active Bladder

DUBLIN - July 17, 2017 - Medtronic plc (NYSE: MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of...
Jul 11, 2017

Clinical Trial to Evaluate Medtronic Cryoablation as First-Line Treatment for Patients With Symptomatic Paroxysmal Atrial Fibrillation

DUBLIN - July 11, 2017 - Medtronic plc (NYSE: MDT) today announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the safety and effectiveness of performing...
Jul 10, 2017

Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval

Self-Expanding CoreValve(TM) Evolut(TM)TAVR Platform with Excellent Procedural Safety and Proven Valve Performance Helps Address Needs of Intermediate-Risk Patients

DUBLIN - July 10, 2017 - Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic...
Jun 28, 2017

Medtronic SureTune(TM)3 Earns CE Mark for Deep Brain Stimulation Therapy

Data Presented at the 17th Quadrennial Meeting of the World Society for Stereotactic and Functional Neurosurgery in Berlin

DUBLIN and BERLIN - June 28, 2017 - Medtronic plc (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for SureTune(TM)3 software for deep brain stimulation (DBS)....
Jun 26, 2017

Medtronic Announces Outcomes-Based Agreement with Aetna for Type 1 and Type 2 Diabetes Patients

DUBLIN - June 26, 2017 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a new outcomes-based agreement with Aetna (NYSE:AET) for type 1 and type 2 diabetes...
Jun 23, 2017

Medtronic Announces 7 Percent Increase in Cash Dividend

40th Consecutive Year of Dividend Increases; Board Authorizes $5 Billion for Share Repurchases

DUBLIN - June 23, 2017 - The board of directors of Medtronic plc (NYSE: MDT) today approved a 7 percent increase in its quarterly cash dividend, raising the quarterly amount to $0.46 per ordinary...
Jun 20, 2017

New Data Reveal Medtronic CRT Devices Improve Therapy Delivery and Reduce Healthcare Costs

Data Presented at EUROPACE 2017 Reinforce Cost and Outcome Benefits of Exclusive EffectivCRT(TM) and AdaptivCRT(TM) Algorithms, Along with Improved Device Longevity

DUBLIN and VIENNA - June 20, 2017 - Medtronic plc (NSYE: MDT) today announced new data showing that use of its cardiac resynchronization therapy (CRT) devices - with its proprietary AdaptivCRT(TM)...

Show per page